Home > Journals > Journal of Neurosurgical Sciences > Past Issues > Journal of Neurosurgical Sciences 2015 March;59(1) > Journal of Neurosurgical Sciences 2015 March;59(1):63-71

CURRENT ISSUEJOURNAL OF NEUROSURGICAL SCIENCES

A Journal on Neurosurgery


Indexed/Abstracted in: e-psyche, EMBASE, PubMed/MEDLINE, Neuroscience Citation Index, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 1,651


eTOC

 

REVIEWS  


Journal of Neurosurgical Sciences 2015 March;59(1):63-71

language: English

Indications and therapeutic management of carotid stenosis in high-risk patients: SAPPHIRE and beyond

Munich S. A. 1, 2, Cress M. C. 1, 2, Krishna C. 1, 2, Levy E. I. 1-4

1 Department of Neurosurgery, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA;
2 Department of Neurosurgery, Gates Vascular Institute/Kaleida Health, Buffalo, NY, USA;
3 Department of Radiology, School of Medicine and Biomedical Sciences, University at Buffalo, State University of New York, Buffalo, NY, USA;
4 Toshiba Stroke and Vascular Research Center, University at Buffalo, State University of New York, Buffalo, NY, USA


PDF  REPRINTS


Carotid artery revascularization is an effective means of stroke prevention in selected patients with carotid stenosis. Traditionally, carotid endarterectomy (CEA) was performed to achieve this goal. With the development of endovascular techniques and technologies, carotid artery stenting (CAS) has become a viable alternative to CEA, particularly in patients considered high risk for CEA. The Stenting and Angioplasty with Protection in Patients at High Risk for Endarterectomy (SAPPHIRE) study single-handedly catapulted CAS to the forefront of therapeutic options for high-risk patients. This study directly compared CAS to CEA in high-risk patients, finding CAS to be equally effective. Since SAPPHIRE, several studies have confirmed the safety and efficacy of CAS in high-risk patients, demonstrating acceptable 1-year morbidity (1-11.3%) and durable target-vessel patency (97.6-98.7%).

top of page